Grant PJ, Conlon A, Chopra V, Flanders SA. Use of venous thromboembolism prophylaxis in hospitalized patients. JAMA Intern Med 2018:21 de mayo. [Ref.ID 102646]

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

Shlomo M, Gorodischer R, Daniel S, Wiznitzer A, Matok I, Fishman B, Koren G, Levy A. The fetal safety of enoxaparin use during pregnancy: a population-based retrospective cohort study. Drug Saf 2017;40:1147-55. [Ref.ID 102105]

Billionnet C, Alla F, Bérigaud É, Pariente A, Maura G. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases . Pharmacoepidemiol Drug Saf 2017;26:535-43. [Ref.ID 101959]

Damen NL, Baines R, Wagner C, Langelaan M. Medication-related adverse events during hospitalization: a retrospective patient record review study in The Netherlands. Pharmacoepidemiol Drug Saf 2017;26:32-9. [Ref.ID 101947]

Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]

Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-1014. JAMA 2016;316:2115-25. [Ref.ID 100973]

Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH, ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. [Ref.ID 100910]

Righini M, Galanaud J-P, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier M-T, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenet C, Accassat S, Robert-Ebadi H, Carrier M, Le Gal G, Mermillod B, Laroche J-P, Bounameaux H, Perrier A, Kahn SR, Quere I. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. The Lancet Haematology 2016:noviembre. [Ref.ID 100906]

Schellong SM. Low risk is not enough: the dilemma of calf vein thrombosis. The Lancet Haematology 2016:7 de noviembre. [Ref.ID 100905]

Nielen JTH, Dagnelie PC, Emans PJ, Veldhorst-Janssen N, Lalmohamed A, Van Staa T-P, Boonen AERCH, van den Bemt BJF, de Vries F. Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiol Drug Saf 2016;25:1245-52. [Ref.ID 100896]

Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Espposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935. [Ref.ID 100794]

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM, for the APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375:534-44. [Ref.ID 100706]

Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016;127:1417-25. [Ref.ID 100222]

Anónimo. Implications of religious and cultural beliefs on selection of medicines. Drug Ther Bull 2016;54:45-8. [Ref.ID 100172]

Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. J Thromb Haemost 2015;13:1590-6. [Ref.ID 99547]

Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009. [Ref.ID 99531]

Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, for the CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86. [Ref.ID 99497]